Publications by authors named "Diz-Tain P"
Article Synopsis
- Immunotherapy treatments show high effectiveness in advanced non-small-cell lung cancer (NSCLC), but the impact of BRAF mutations in these cases is unclear.
- In a study of 116 stage IIIA/B and 84 stage IV patients, BRAF mutations were found in a small percentage, with all patients who had these mutations remaining alive and disease-free at the study's cutoff.
- BRAF-mutated patients had a 100% pathological complete response rate to neoadjuvant chemoimmunotherapy compared to a 44.3% rate in BRAF wild-type patients, suggesting that BRAF mutations could indicate better outcomes for those undergoing immunotherapy.
Article Synopsis
- The study aimed to assess the incidence of ALK translocations in advanced/non-small cell lung cancer (NSCLC) patients in Spain and the clinical characteristics of those affected.
- Out of 559 patients, 5.5% had ALK translocations, with these patients generally being younger, mostly female, and non-smokers.
- Treatment with crizotinib showed a 59.3% objective response rate, with median progression-free survival of 15.8 months and overall survival of 46.5 months; most patients reported stable or improved quality of life during treatment.
Introduction: 10-16% of non-small cell lung cancer (NSCLC) cases have the epidermal growth factor receptor (EGFR) amplified and/or mutated. Studies show that EGFR tyrosine kinase inhibitors (TKIs) significantly prolong progression-free survival (PFS) in patients with advanced NSCLC compared to those treated with platinum-based chemotherapy (CT) doublets. Our aim is to perform a real-world survival analysis of patients treated with TKI as first-line therapy at the Hospital of Leon (CAULE) in Spain.
View Article and Find Full Text PDFBackground: Anti-angiogenic agents are reported to exert clinical activity in patients with epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC). We evaluated the outcomes of the combination of docetaxel plus nintedanib in refractory NSCLC patients harboring EGFR mutations.
Methods: We retrospectively analyzed 19 patients with advanced EGFR-mutant NSCLC who had progressed to EGFR tyrosine kinase inhibitors (TKI) and platinum-based chemotherapy receiving docetaxel and nintedanib at 14 Spanish institutions from January 2013 to December 2019.
Purpose: The analysis of epidermal growth factor receptor (EGFR) mutations in many patients with advanced non-small-cell lung cancer (aNSCLC) has provided the opportunity for successful treatment with specific, targeted EGFR tyrosine kinase inhibitors. However, this therapeutic decision may be challenging when insufficient tumor tissue is available for EGFR mutation testing. Therefore, blood surrogate samples for EGFR mutation analysis have been suggested.
View Article and Find Full Text PDFAfatinib, together with gefitinib and erlotinib, is approved for first-line treatment of advanced non-small cell lung cancer (NSCLC) with activating mutations of the epidermal growth factor receptor (EGFR). This is an irreversible inhibitor of the ErbB family, acting on EGFR (HER1, ErbB1), ErbB2 (HER2) and ErbB4 (HER4). Covalent attachment to cysteine residues in the catalytic domain of EGFR, HER2 and ErbB4 inhibits the tyrosine kinase activity (TKIs) of these receptors, decreasing auto- and transphosphorylation between ErbB dimers, and thus blocking the activity of downstream signalling pathways related to growth and apoptosis suppression.
View Article and Find Full Text PDF